Previous 10 | Next 10 |
CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executive Officer Dr. Dwain K. Irvin will be participating in the National Brain Tumor Society's (NBTS) ...
CLEVELAND, OH and BANGKOK, THAILAND / ACCESSWIRE / June 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced a partnership with Thailand-based CKN Ventures Limited, a multifaceted clinical and commercial he...
CLEVLAND, OH / ACCESSWIRE / June 1, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the formation of its Precision Medicine Division to enable more enhanced and accelerated personalized therapeutics and tr...
Report Details Promise of Adaptive Cancer Immunotherapy in Treating Highly Malignant Brain Tumors Recent Achievements for Glioblastoma/Brain Tumor Treatment to be Addressed in Upcoming Presentation at World Orphan Drug Congress CLEVELAND, OH / ACCESSWIRE / May 11, 2023 / NovAccess Globa...
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award CLEVELAND, OH / ACCESSWIRE / March 15, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, announced that Dr. Christopher Wheeler, ...
CLEVELAND, OH / ACCESSWIRE / February 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX) , a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dwain Irvin has been invited to present at the World Orphan Drug Congress, scheduled for May 23-...
Dr. Christopher Wheeler, NovAccess Lead Scientist, to Receive Leadership Award for his Contributions CLEVELAND, OH / ACCESSWIRE / February 3, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CE...
Topic: Immunotherapy Advantages Over Surgical Treatment CLEVELAND, OH / ACCESSWIRE / January 5, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its latest monthly installment in ...
Topic: Benefits of Immunotherapies Versus Conventional Chemotherapy for Patients and Their Support Networks CLEVELAND, OH / ACCESSWIRE / November 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announce...
Invites all Shareholders and Investors to Participate CLEVELAND, OH / ACCESSWIRE / November 8, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its annual meeting of shareholders will take pla...
News, Short Squeeze, Breakout and More Instantly...
CLEVELAND, OH / ACCESSWIRE / May 21, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a pioneering biomedical company developing innovative immunotherapies for brain tumor patients, today announced it has submitted a provisional patent for new intellectual property developed at Cedars-Sinai to advance...
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held in May 2024. The Company ...
CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous system, today announced the procurement of a new intellectual property license from Cedars-Sinai Medi...